



# Risk Factors And Complications of Arteriovenous Fistula In Patients on Chronic Hemodialysis

Damir N. Peličić<sup>1,2</sup>

<sup>1</sup> Clinical Center of Montenegro, Podgorica, Montenegro

<sup>2</sup> Faculty of Medicine, University of Montenegro, Podgorica, Montenegro

## SUMMARY

**Introduction:** Arteriovenous fistula (AVF) is a surgical connection created between an adjacent artery and vein in patients undergoing chronic hemodialysis. The aim is to divert arterial blood into a vein, which becomes arterialized due to the newly established hemodynamics. AVF is widely recommended as the preferred vascular access for hemodialysis (HD), due to long-term therapy of patients with end-stage renal disease and significantly fewer complications compared to other vascular access options, such as Central Venous Catheter (CVC). However, despite the lower complication rate, AVF can still be associated with intraoperative, early, and late postoperative complications.

**Methodology:** Recent scientific publications were thoroughly reviewed through PubMed, Scopus, SCI Index and other reference databases with a focus on risk factors and complications of arteriovenous fistula in patients on a chronic HD program.

**Topic:** The most common AVF complications include: stenosis caused by hemodynamic and functional changes that cause narrowing of the blood vessel lumen by more than 50% and occurs on both the arterial and venous sides of the AV fistula. Thrombosis, which is the complete cessation of blood flow in the AVF venous segment proximal to the AV anastomosis. Aneurysm is a local expansion of a vein resulting from strong blood flow through the site of narrowing. Then the infection of the anastomosis that occurs due to careless and non-aseptic puncturing of the AVF and other complications of the AV fistula, such as pseudoaneurysm, hematoma, peripheral ischemia and heart complications.

**Conclusion:** Thrombosis and stenosis are among the most common late complications of AVFs. This paper highlights the significance of AVFs as a permanent vascular access for hemodialysis and reviews the various complications and their associated risk factors. Scientific evidence from the literature emphasizes that proper and consistent AVF puncture technique can significantly delay the onset of these complications, underlining the importance of careful preoperative and ongoing management.

**Keywords:** Chronic Kidney Disease, Hemodialysis, Thrombosis, Aneurysm

## INTRODUCTION

Chronic kidney disease (CKD) is defined as permanent and irreversible kidney function damage, characterized by a reduced glomerular filtration rate persisting for three months or

more along with a sustained decline in glomerular filtration capacity [1,2]. In the terminal stage of CKD, there are three modalities for renal function replacement: HD, Peritoneal Di-

Corresponding author:

Associate in teaching Damir N. Peličić, PhD

Specialist in Health Care

Clinical Centre of Montenegro, Ljubljanska bb, 81000 Podgorica, Montenegro

E-mail: damir.pelicic@t-com.me

alysis (PD), and Kidney Transplantation (KTx) [3]. To access treatment for patients on HD, it is necessary to create certain prerequisites, including providing adequate vascular access, which can be temporary CVC or permanent vascular access AVF and Arteriovenous Graft (AVG). AVF is recommended as the preferred vascular access option for HD due to its suitability for chronic hemodialysis patients and significantly fewer complications compared to other vascular access types such as CVC [4]. However, despite the lower complication rate, AVF may still be associated with intraoperative, early, and late postoperative complications [5]. This paper provides an overview of the importance of AVF as a permanent blood access for HD along with its associated complications and the risk factors contributing to their development.

## METHODOLOGY

In our article, we reviewed recent scientific original publications and meta-analyses, which we thoroughly studied through PubMed, Scopus, SCI Index and other reference databases with a focus on risk factors and complications of arteriovenous fistula in patients on a chronic HD program. The keywords we used to search for scientific articles were related to: Chronic renal failure, complications, Arteriovenous fistula, hemodialysis, central venous catheter, thrombosis, aneurysm, risk factors and others.

## TOPIC

An arteriovenous fistula (AVF) is a surgically created connection between an adjacent artery and vein in patients undergoing hemodialysis (HD), designed to divert arterial blood into the venous system, which becomes arterialized due to the resulting hemodynamic changes [6-8]. The global incidence of CKD is increasing rapidly, along with the prevalence of patients on HD. Among patients with CKD, HD is the most commonly used form of dialysis, commonly used 89% of the dialysis population, while PD accounts for the remaining 11% [9-12]. The indication for creating AVF is in patients with an endogenous creatinine clearance  $\leq 20$  mL/min/1.73 m<sup>2</sup>. An internal diameter of the radial artery  $\geq 2.0$  mm, internal diameter of the cephalic vein  $\geq 2.5$  mm, blood flow velocity through the radial artery ( $V_{maxS}$ )  $\geq 50$  cm/s, and blood flow through the radial ar-

tery ( $Q_{a.radialis}$ )  $\geq 40$  mL/min ensure proper maturation of the distal radio-cephalic AVF. Maturation is considered adequate when, four to five weeks postoperatively, the cephalic vein diameter reaches  $\geq 4.0$  mm and blood flow exceeds 500 mL/min, indicating readiness for AVF puncture. In terms of HD treatment efficiency, guidelines suggest that AVFs should support a blood flow velocity of 100–350 cm/s and a blood flow rate of 500–1000 mL/min to ensure effective dialysis delivery [13]. AVF is essentially an anastomosis between the radial artery and cephalic vein (known as Brescia-Cimino fistula). Under constant arterial blood pressure, the venous part of the fistula undergoes dilation (6–10 mm) and thickening, a process called „maturation“. This maturation process should last at least a month, ideally 3 to 4 months after the surgical procedure performed by a vascular surgeon, except in patients with type 2 diabetes, the elderly, and patients with cardiovascular insufficiency or other chronic diseases [1-3]. Early and appropriate planning of vascular access ensures good access, preventing complications associated with CVC and other HD complications [14,15]. AVF is the standard and best vascular access for HD patients. In some patients with inadequate blood vessels, a proximal arteriovenous fistula may need to be created, or an AVG may be implanted. Literature suggests that such a procedure is practiced in patients without other options for creating vascular access. In the dialysis center of the Clinical Center of Montenegro, the number of AVF is about 80 percent compared to CVC [16]. The growing prevalence of end-stage CKD has led to a sharp increase in the number of HD patients due to longer life expectancy. AVF is the optimal blood access for HD due to its longevity, lower rates of infection and thrombosis, and greater safety compared to AVG or CVC [17-19]. The most common AVF complications by frequency of occurrence in patients on HD (Table 1.).

### Thrombosis AVF

The most common complications of AVF include stenosis caused by hemodynamic and functional changes that result in a narrowing of the vessel lumen by more than 50%. It is important to emphasize that stenosis can precede AVF thrombosis and occurs on both the arterial and venous sides of the AV fistula [20,21].

**Table 1.** The most common AVF complications by frequency of occurrence in patients on HD

| The most common AVF complications by frequency of occurrence in patients on HD | Some of the risk factors for AVF complications                                                                                                                                    |
|--------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Thrombosis AVF                                                                 | Stenosis, hypercoagulability and narrowing of blood flow due to access occlusion with too tight bandages or clamps during the hemostasis period, heart failure, hypotension, etc. |
| Aneurysm AVF                                                                   | Increased venous pressure due to central venous stenosis, repeated punctures at the same puncture site, infections, etc.                                                          |
| Infection AVF                                                                  | Inexpert puncture and failure to adhere to aseptic measures, inadequate hygiene and patient care, etc.                                                                            |

Thrombosis results in the complete cessation of blood circulation in the venous segment of the AVF, proximal to the AV anastomosis [20,21]. Regarding complications associated with vascular access for HD, thrombosis, along with stenosis, is among the most common late complications of AVF, with an incidence ranging from 17% to 25% [20,21]. According to the literature, significant predictors for the development of thrombosis in the first AVF in HD patients were a body mass index > 25 kg/m<sup>2</sup>, blood pressure > 140/90 mmHg, and an age category of 45-59 years [21,22]. The most common cause of vascular access failure is thrombosis [23-27]. The three primary causes of AVF failure or thrombosis are: inadequate venous outflow (stenosis), inadequate arterial blood inflow, and medical factors, including heart failure and reduced hypotension [23-27]. A study by Miller et al. suggests that thrombosis is the most common complication in the female population, which they explain by the poor development of blood vessels in women, unlike the male population [28].

### Aneurysm AVF

An aneurysm is defined as a localized dilation of a vein due to strong blood flow through the narrowed area. Infection of the anastomosis occurs due to improper and non-aseptic puncturing of the AVF, and other complications of surgical AVF include pseudoaneurysms, hematomas, peripheral ischemia, and cardiovascular complications [20,21]. A study by Jankovic A et al.'s involving 181 HD patients found that 150 were eligible for inclusion in the study. Aneurysmal changes were found in 90 (60%) patients, with most having two or more aneurysms at one AVF flow site [29]. Patients with poorly controlled long-term diabetes mellitus on HD have a 5.8 times higher risk of developing AVF aneurysms compared to others. The study also reported a higher incidence of aneurysms in patients who had been on high-flow dialysis membranes for a

longer period and with higher blood flow rates [29]. Between August 2010 and August 2013 in the United States, the use of AVF increased from 63% to 68%, while CVC usage decreased from 19% to 15% [30]. Aneurysms are now recognized as one of the most common and severe complications vascular access for HD [31]. Dilatation of more than three times the original diameter of the natural blood vessel is considered an aneurysm, confirmed by ultrasound scanning [32]. Literature suggests that long-term patency of AVF is the most relevant factor for the treatment of patients with end-stage kidney failure on HD [33]. Al-Thani H et al.'s study suggests that the overall mortality rate from all causes related to AVF was 37.5%, with the leading causes of death being sepsis/pneumonia (60%), myocardial infarction, and heart failure (40%). These findings underscore the high morbidity and mortality associated with AVF aneurysms in HD patients [34]. Hang F et al.'s study, which aimed to investigate risk factors for AVF dysfunction, concluded that sex, body weight, and phosphorus levels were independent risk factors for AVF dysfunction [35]. They found that AVF dysfunction was significantly associated with several risk factors, including body weight, phosphorus levels, and sex. Therefore, weight loss or oral phosphate binders can significantly improve the long-term success of AVF [35]. Zhang et al., in a comprehensive meta-analysis involving 27 studies (including 24 cohort studies, two case-control studies, and one cross-sectional study), identified the following as independent risk factors for AVF thrombosis: advanced age, female sex, elevated C-reactive protein (CRP) levels, distal fistula location, hypertension, low levels of CD34<sup>+</sup>KDR<sup>+</sup> cells, and erythropoietin use [36]. A study by Erkut B et al., who followed 412 HD patients with AVF implantation over a 10-year period, suggests that vascular access occlusion leads to significant morbidity in HD patients. Age, sex, diabetes mellitus, malignancy, tobacco smoking, heparin use after one HD treatment,

previous placement of a dialysis CVC, number of HD therapy treatments, and AVF location may be associated with primary AVF survival. The authors of some studies concluded that risk factors affecting primary AVF patency were diabetes mellitus ( $p = 0.0001$ ), number of hemodialysis sessions  $\geq 3$  per week ( $p < 0.0005$ ), presence of malignancy ( $p < 0.0005$ ), previous dialysis CVC ( $p < 0.0007$ ), and post-HD ( $p < 0.0007$ ) [33].

### Infection AVF

Infection is associated with CVC and other HD complications [14,15]. The literature suggests that CVC and AVG infections are more common than AVF infections [37]. In a study by Liu et al., there were 2119 patients from a HD center in the China National Kidney Data System between January 1, 2010, and October 10, 2023. Multivariate analysis showed that a high comorbidity score from blood access complications for HD was a risk factor for death, of which infection was a significant factor [38]. An insufficiently mature or developed AVF may increase the infection rate and mortality in hemodialysis patients [39]. AVF infections are less common than CVC infections by as much as 90% in HD patients [40]. The literature suggests that incompetent AVF cannulation by nurses is associated with an increased risk of infection in HD patients [41].

### Risk factors and complications of AVF

Heart failure is the most prevalent cardiovascular disease associated with CKD and represents a high risk for cardiovascular mortality in patients with HD. Heart failure is particularly high risk during the period of AVF maturation due to the pronounced hemodynamic changes associated with the large increase in blood flow, as well as in the first 120 days after initiating HD. Studies suggest that AVF creation in the high-flow brachial artery should be avoided because this is the highest risk of worsening cardiac function in the patient [42]. Some studies suggest that the AVF maturation process should last from 6 to 16 weeks, and it is important to note that in patients with uncontrolled and long-term diabetes and elderly patients, this AVF maturation process can last up to 6 months [43,44]. A meta-analysis by Almasri et al. found that patients with diabetes and advanced vascular complications, such

as atherosclerosis, have a shorter duration of AVF patency than other patients on HD [45]. The establishment of a well-functioning AVF in patients on a chronic HD is essential, as it reduces reliance on central venous catheters (CVCs) [46-50]. Individual factors such as comorbidities, AVF anatomy, remaining dialysis access options, and patient preferences should be considered when planning a surgical approach for HD [49]. Loss of AVF patency in patients on HD significantly leads to a greater number of intraoperative and postoperative complications and is significantly associated with a number of modifiable risk factors, the early recognition and elimination of which risk factors can improve AVF functioning and extend its exploitation time [51]. Preventive interventions in AVF reduce the incidence of complications and improve blood flow in the AVF. In this way, they reduce negative emotions in HD patients such as anxiety and depression, and significantly improve the patient's quality of life, thereby increasing patient satisfaction with care [52].

## CONCLUSION

Arteriovenous fistula (AVF) remains the gold standard for vascular access in hemodialysis (HD). However, non-functioning AVFs, due to the aforementioned complications, often necessitate the use of central venous catheters (CVCs), which are associated with significantly higher morbidity and mortality rates in patients undergoing chronic HD. The successful and timely placement of AVF is a key indicator for preventing complications in HD patients. The importance of a well-created AVF in patients on a chronic HD program, then a well-cared-for AVF by nurses results in reduced hospitalizations, fewer emergency dialysis procedures, and reduced CVC use, which suggests that such models could potentially significantly reduce overall health care costs. A review of scientific evidence in the relevant scientific literature on preoperative management of this vascular access has determined that long-term and correct puncturing of AVF in HD, along with proper aseptic and antiseptic measures, prevents and significantly delays the occurrence of AVF complications, reduce patient mortality, and enhance the overall quality of life for individuals receiving chronic HD.

## CONFLICT OF INTEREST

The author declares no conflict of interest.

## REFERENCES

1. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Ann Intern Med.* 2003 Jul 15;139(2):137-47. doi: 10.7326/0003-4819-139-2-200307150-00013.
2. Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. *Ann Intern Med.* 2013 Jun 4;158(11):825-30. doi: 10.7326/0003-4819-158-11-201306040-00007.
3. Đurić PS, Popović J, Janković A, Tošić J, Dimković N. Parameters of hemodialysis adequacy and patients' survival depending on treatment modalities. *Med Pregl.* 2015;68(7-8):251-7.
4. Lalović N, Maksimović Z, Maksimović S. Late postoperative complications of arteriovenous fistula for hemodialysis. *Biomedicinska istraživanja.* 2021;12(1):69-80.
5. Aljuaid MM, Alzahrani NN, Alshehri AA, Alkhalid LH, Alosaimi FS, Aljuaid NW, Asiri OA, Atalla AA. Complications of arteriovenous fistula in dialysis patients: Incidence and risk factors in Taif city, KSA. *J Family Med Prim Care.* 2020 Jan 28;9(1):407-411. doi: 10.4103/jfmpc.jfmpc\_848\_19.
6. Halovanić G. Pristupi krvotoku za hemodijalizu. *Sestrinski glasnik [Internet].* 2015 [pristupljeno 21.02.2025.];20(1):64-67. <https://doi.org/10.11608/sgnj.2015.20.013>
7. Oliver MJ. The Science of Fistula Maturation. *J Am Soc Nephrol.* 2018 Nov;29(11):2607-2609.
8. Marsh AM, Genova R, Buicko Lopez JL. Dialysis Fistula. [Updated 2023 May 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559085/>
9. Pecoits-Filho R, Okpechi IG, Donner JA, Harris DCH, Aljubori HM, Bello AK, Bellorin-Font E, Caskey FJ, Collins A, Cueto-Manzano AM, Feehally J, Goh BL, Jager KJ, Nangaku M, Rahman M, Sahay M, Saleh A, Sola L, Turan Kazancioglu R, Walker RC, Walker R, Yao Q, Yu X, Zhao MH, Johnson DW. Capturing and monitoring global differences in untreated and treated end-stage kidney disease, kidney replacement therapy modality, and outcomes. *Kidney Int Suppl* (2011). 2020 Mar;10(1):e3-e9. doi: 10.1016/j.kisu.2019.11.001.
10. Murad MH, Elamin MB, Sidawy AN, Malaga G, Rizvi AZ, Flynn DN, Casey ET, McCausland FR, McGrath MM, Vo DH, El-Zoghby Z, Duncan AA, Tracz MJ, Erwin PJ, Montori VM. Autogenous versus prosthetic vascular access for hemodialysis: a systematic review and meta-analysis. *J Vasc Surg.* 2008 Nov;48(5 Suppl):34S-47S. doi: 10.1016/j.jvs.2008.08.044.
11. Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access and mortality in U.S. hemodialysis patients. *Kidney Int* 2001;60(4):1443-51.
12. Bulajić JB, Knežević VV. Management of peritoneal dialysis related infections. *Hospital Pharmacology - International Multidisciplinary Journal* . 2024;11(1):1382-95. doi: 10.5937/hpimj2401382B
13. Petrović D. Klinički značaj color doppler ultrasonografije u preoperativnom planiranju izrade vaskularnog pristupa za hemodijalizu. *Sanamed.* 2012;7(2):113-8.
14. Till V, Avramov P, Vučaj Čirilović V, Popović V, Lučić M. Fiksacija stent-grafta nakon venske dislokacije kod bolesnika sa femoralnom post-traumatskom arteriovenskom fistulom. *Vojnosanitetski pregled.* 2013;70(6):612-4. doi: 10.2298/VSP1306612T
15. Jagić N, Petrović D, Miloradović V, Novaković B. Klinički značaj otkrivanja rane insuficijencije vaskularnog pristupa za hemodijalizu. *Medicus.* 2006;7(3):107-11.
16. Donfrid BS, Lozanče OB, Stefanović ZB, Janković AN, Dimković NB. Podlakatni brahio-bazilični arteriovenski graft za hemodijalizu u dva akta. *Srpski arhiv za celokupno lekarstvo.* 2018;146(5-6):316-9. doi: 10.2298/SARH161228138D
17. Ravani P, Palmer SC, Oliver MJ, Quinn RR, MacRae JM, Tai DJ, Pannu NI, Thomas C, Hemmelgarn BR, Craig JC, Manns B, Tonelli M, Strippoli GF, James MT. Associations between hemodialysis access type and clinical outcomes: a systematic review. *J Am Soc Nephrol.* 2013 Feb;24(3):465-73. doi: 10.1681/ASN.2012070643.
18. Masengu A, Maxwell AP, Hanko JB. Investigating clinical predictors of arteriovenous fistula functional patency in a European cohort. *Clin Kidney J.* 2016 Feb;9(1):142-7. doi: 10.1093/ckj/sfv131.
19. Roy-Chaudhury P, Kruska L. Future directions for vascular access for hemodialysis. *Semin Dial.* 2015 Mar-Apr;28(2):107-13. doi: 10.1111/sdi.12329.
20. Stirbu O, Gadalean F, Pitea IV, Ciobanu G, Schiller A, Grosu I, Nes A, Bratescu R, Olariu N, Timar B, Tandrau MC. C-reactive protein as a prognostic risk factor for loss of arteriovenous fistula patency in hemodialyzed patients. *J Vasc Surg.* 2019 Jul;70(1):208-215. doi: 10.1016/j.jvs.2018.10.100.
21. Stipanićev A, Čičak M, Mamić J, Filipović M, Novosel L, Sjekavica I. Endovaskularno stvaranje arteriovenske fistule za pristup hemodijalizi. *Radiološki vjesnik [Internet].* 2023 [pristupljeno 18.02.2025.];47(1):28-32. <https://doi.org/10.55378/rv.47.1.3>

22. Novković M, Knežević V, Petrović L. Risk factors for the formation of arteriovenous fistula thrombosis in patients treated with chronic hemodialysis. *Medicinski pregled*. 2023;76(11-12):311-7. doi: 10.2298/MPNS2312311N
23. Rajan DK, Falk A. A randomized prospective study comparing outcomes of angioplasty versus VIABAHN stent-graft placement for cephalic arch stenosis in dysfunctional hemodialysis accesses. *J Vasc Interv Radiol* 2015;26(9):1355-61.
24. Malik J, Tuka V, Kasalova Z, Chytilova E, Slavikova M, Clagett P, Davidson I, Dolmatch B, Nichols D, Gallieni M. Understanding the dialysis access steal syndrome. A review of the etiologies, diagnosis, prevention and treatment strategies. *J Vasc Access*. 2008 Jul-Sep;9(3):155-66. PMID: 18850575.
25. Zanow J, Petzold K, Petzold M, Krueger U, Scholz H. Flow reduction in high-flow arteriovenous access using intraoperative flow monitoring. *J Vasc Surg* 2006;44(6):1273-8.
26. Miles AM. Upper limb ischemia after vascular access surgery: differential diagnosis and management. *Semin Dial* 2000;13(5):312-5. Complications of arteriovenous fistulae: beyond venous stenosis. *Adv Chronic Kidney Dis* 2012;19(3):195-201.
27. Shojaiepard A, Khorgami Z, Kouhi A, Kohan L. Surgical management of aneurismal dilation of vein and pseudoaneurysm complicating hemodialysis arteriovenous fistula. *Indian J Surg* 2007;69(6):230-6. Epub 2008 Jan 28.
28. Miller CD, Robbin ML, Allon M. Gender differences in outcomes of arteriovenous fistulas in hemodialysis patients. *Kidney Int*. 2003 Jan;63(1):346-52. doi: 10.1046/j.1523-1755.2003.00740.x.
29. Jankovic A, Donfrid B, Adam J, Ilic M, Djuric Z, Damjanovic T, Popovic J, Popovic G, Radojicic Z, Dimkovic N. Arteriovenous fistula aneurysm in patients on regular hemodialysis: prevalence and risk factors. *Nephron Clin Pract*. 2013;124(1-2):94-8. doi: 10.1159/000355548.
30. Pisoni RL, Zepel L, Port FK, Robinson BM. Trends in US Vascular Access Use, Patient Preferences, and Related Practices: An Update From the US DOPPS Practice Monitor With International Comparisons. *Am J Kidney Dis*. 2015 Jun;65(6):905-15. doi: 10.1053/j.ajkd.2014.12.014. Epub 2015 Feb 7.
31. Mudoni A, Cornacchiari M, Gallieni M, Guastoni C, McGrogan D, Logias F, Ferramosca E, Mereghetti M, Inston N. Aneurysms and pseudoaneurysms in dialysis access. *Clin Kidney J*. 2015 Aug;8(4):363-7. doi: 10.1093/ckj/sfv042. Epub 2015 Jun 10.
32. Pasklinsky G, Meisner RJ, Labropoulos N, Leon L, Gasparis AP, Landau D, Tassiopoulos AK, Pappas PJ. Management of true aneurysms of hemodialysis access fistulas. *J Vasc Surg*. 2011 May;53(5):1291-7. doi: 10.1016/j.jvs.2010.11.100.
33. Parmar J, Aslam M, Standfield N. Pre-operative radial arterial diameter predicts early failure of arteriovenous fistula (AVF) for haemodialysis. *Eur J Vasc Endovasc Surg*. 2007 Jan;33(1):113-5. doi: 10.1016/j.ejvs.2006.09.001. Epub 2006 Oct 9.
34. Al-Thani H, El-Menyar A, Al-Thani N, Asim M, Hussein A, Sadek A, Sharaf A, Fares A. Characteristics, Management, and Outcomes of Surgically Treated Arteriovenous Fistula Aneurysm in Patients on Regular Hemodialysis. *Ann Vasc Surg*. 2017 May;41:46-55. doi: 10.1016/j.avsg.2016.08.046. Epub 2017 Feb 24.
35. Zhang F, Li J, Yu J, Jiang Y, Xiao H, Yang Y, Liang Y, Liu K, Luo X. Risk factors for arteriovenous fistula dysfunction in hemodialysis patients: a retrospective study. *Sci Rep*. 2023 Dec 3;13(1):21325. doi: 10.1038/s41598-023-48691-4.
36. Zhang Y, Yi J, Zhang R, Peng Y, Dong J, Sha L. Risk Factors for Arteriovenous Fistula Thrombus Development: A Systematic Review and Meta-Analysis. *Kidney Blood Press Res*. 2022;47(11):643-653. doi: 10.1159/000526768. Epub 2022 Sep 16.
37. Besarab, A., Frinak, S., Margassery, S., & Wish, J. B. (2024). Hemodialysis Vascular Access: A Historical Perspective on Access Promotion, Barriers, and Lessons for the Future. *Kidney medicine*, 6(9), 100871. <https://doi.org/10.1016/j.xkme.2024.100871>
38. Liu RX, Lin S, Liu L, Xu J, Liu LN, Pang J, An HW, Yang WQ, Jian JL, Wang J, He ZL, Luo XL, Zou H, Zeng Y, Huang QX, Li YL. Vascular access type and prognosis in elderly hemodialysis patients: a propensity-score-matched study. *Ren Fail*. 2024 Dec;46(2):2387205. doi: 10.1080/0886022X.2024.2387205.
39. Morgans HA, De Souza HG, Richardson T, Claes D, Barton KT, Lee M, Mahesh S, Muff-Luett M, Swartz SJ, Neu A, Warady B; SCOPE Collaborative. A comparison of the buttonhole and rope-ladder AVF cannulation techniques and infection rates within the SCOPE collaborative. *Pediatr Nephrol*. 2021 Dec;36(12):3915-3921. doi: 10.1007/s00467-021-05137-1.
40. Fonseca AV, Toledo Barros MG, Baptista-Silva JC, Amorim JE, Vasconcelos V. Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts. *Cochrane Database Syst Rev*. 2024 Feb 14;2(2):CD013293. doi: 10.1002/14651858.CD013293.
41. Labriola L, Crott R, Desmet C, Romain C, Jadoul M. Infectious complications associated with buttonhole cannulation of native arteriovenous fistulas: a 22-year follow-up. *Nephrol Dial Transplant*. 2024 May 31;39(6):1000-1007. doi: 10.1093/ndt/gfad229.
42. Erkut B, Unlü Y, Ceviz M, Becit N, Ateş A, Colak A, Koçak H. Primary arteriovenous fistulas in the forearm for hemodialysis: effect of miscellaneous factors in fistula patency. *Ren Fail*. 2006;28(4):275-81. doi: 10.1080/08860220600583617.

43. Roca-Tey R. Permanent arteriovenous fistula or catheter dialysis for heart failure patients. *J Vasc Access*. 2016 Mar;17 Suppl 1:S23-9. doi: 10.5301/jva.5000511.
44. Alfano G, Fontana F, Iannaccone M, Noussan P, Cappelli G. Preoperative management of arteriovenous fistula (AVF) for hemodialysis. *J Vasc Access*. 2017 Nov 17;18(6):451-463. doi: 10.5301/jva.5000771.
45. Almasri J, Alsawas M, Mainou M, Mustafa RA, Wang Z, Woo K, Cull DL, Murad MH. Outcomes of vascular access for hemodialysis: A systematic review and meta-analysis. *J Vasc Surg*. 2016 Jul;64(1):236-43. doi: 10.1016/j.jvs.2016.01.053.
46. Shingarev R, Barker-Finkel J, Allon M. Association of hemodialysis central venous catheter use with ipsilateral arteriovenous vascular access survival. *Am J Kidney Dis*. 2012 Dec;60(6):983-9. doi: 10.1053/j.ajkd.2012.06.014.
47. Fishbane S, Agoritsas S, Bellucci A, Halinski C, Shah HH, Sakhiya V, Balsam L. Augmented Nurse Care Management in CKD Stages 4 to 5: A Randomized Trial. *Am J Kidney Dis*. 2017 Oct;70(4):498-505. doi: 10.1053/j.ajkd.2017.02.366.
48. Knežević VA, Petrović LV, Đurđević Mirković T, Čelić DM. Brain abscess: A rare complication of catheter: Associated infection in patients on hemodialysis. *Hospital Pharmacology - International Multidisciplinary Journal*. 2018;5(1):590-5. doi: 10.5937/hpimj1801590K
49. Chang R, Alabi O, Mahajan A, Miller JS, Bhat KR, Mize BM, Khader MA, Teodorescu V. Arteriovenous fistula aneurysmorrhaphy is associated with improved patency and decreased vascular access abandonment. *J Vasc Surg*. 2023 Mar;77(3):891-898. e1. doi: 10.1016/j.jvs.2022.10.054. Epub 2022 Nov 8.
50. Gagliardi GM, Rossi S, Condino F, Mancuso D, Greco F, Tenuta R, Savino O, Bonofiglio R, Domma F, Latorre G. Malnutrition, infection and arteriovenous fistula failure: is there a link? *J Vasc Access*. 2011 Jan-Mar;12(1):57-62. doi: 10.5301/jva.2010.5831.
51. Maksimović Z, Tasić N, Maksimović S, Gavrić N. Faktori povezani sa gubitkom prohodnosti arteriovenske fistule za hemodijalizu. *Biomedicinska istraživanja*. 2018;9(1):46-55. doi: 10.7251/BII1801046M
52. Yu L, Xu X. The Effectiveness of Preventive Nursing Interventions in Patients on Hemodialysis with Arteriovenous Fistulas and Their Value in Preventing Complications. *Altern Ther Health Med*. 2024 Aug;30(8):366-371.

# Faktori rizika i komplikacije arterio venske fistule kod bolesnika na hroničnom programu hemodijalize

Damir N. Pelić<sup>1,2</sup>

<sup>1</sup> Klinički centar Crne Gore, Podgorica, Crna Gora

<sup>2</sup> Medicinski fakultet, Univerziteta Crne Gore, Podgorica, Crna Gora

## KRATAK SADRŽAJ

**Uvod:** Arteriovenska fistula (AVF) je hirurška procedura gde se spoj koji se izvodi kod bolesnika na hroničnom programu hemodijalize, između susjedne arterije i vene, s ciljem preusmjerenja arterijske krvi u vensku krv, koja se arterijalizira u venu zahvaljujući novorazvijenoj hemodinamici. AVF se preporučuje kao najpoželjna opcija vaskularnog pristupa za hemodijalizu (HD), zbog dugogodišnje terapije kod bolesnika sa terminalnom bubrežnom insuficijencijom i znatno manjeg broja komplikacija u poređenju sa drugim tipovima vaskularnog pristupa, kao što je Centralni Venski Kateter (CVC). Međutim, uprkos nižoj stopi komplikacija, AVF još uvek može biti povezana s intraoperativnim, ranim i kasnim postoperativnim komplikacijama.

**Metodologija:** Najnovije naučne publikacije temeljno su pregledane putem PubMed-a, Scopusa, SCI Indexa i drugih referentnih naučnih baza, s fokusom na faktore rizika i komplikacije AVF kod bolesnika na hroničnom programu HD.

**Tema:** Najčešće komplikacije kod AVF su: stenoza izazvana hemodinamskim i funkcionalnim promenama koje uzrokuju suženje lumena krvnog suda veće od 50 % i javlja se i na arterijskoj i na venskoj strani AV fistule. Kod tromboze je potpuni prestanak cirkulacije krvi u venskom segmentu AVF proksimalnije od AV anastomoze. Aneurizma je lokalno proširenje vene kao posledica jakog strujanja krvi kroz mesto suženja. Zatim Infekcija anastomoze koja se javlja zbog nepažljivog i neaseptičnog punktiranja AVF i ostale komplikacije AV fistule, kao što su pseudoaneurizma, hematom, periferna ishemija i komplikacije na srcu.

**Zaključak:** Može se reći da je tromboza, uz stenozu, među najčešćim kasnim komplikacijama AVF. U ovom radu smo dali osvrt na značaj AVF kao stalnog krvnog pristupa za HD i na komplikacije AVF, kao i na potencijalne faktore rizika koji do njih dovode. Pregledom naučnih dokaza u relevantnoj literaturi, o preoperativnom zbrinjavanju ovog vaskularnog pristupa utvrđeno je da dugotrajna i pravilna punkcija AVF-a sprečava i značajno odgađa nastanak komplikacija AVF-a.

**Ključne reči:** hronična bubrežna slabost, hemodijaliza, tromboza, aneurizma

Received: February 27, 2025

Accepted: March 4, 2025